Advertisement
IMVT vs NAMS
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMVT is a Hold and NAMS is a Hold.
IMVT's Indicator enters downward trend
The Aroon Indicator for IMVT entered a downward trend on October 22, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 226 similar instances where the Aroon Indicator formed such a pattern. In 198 of the 226 cases the stock moved lower. This puts the odds of a downward move at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMVT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMVT's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 60 cases where IMVT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Moving Average Convergence Divergence (MACD) for IMVT just turned positive on October 22, 2026. Looking at past instances where IMVT's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +6.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMVT advanced for three days, in 204 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
IMVT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.173) is normal, around the industry mean (2.973). P/E Ratio (-10.356) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 63 (best 1 - 100 worst), indicating steady price growth. IMVT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
NAMS's Indicator enters downward trend
The Aroon Indicator for NAMS entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 166 similar instances where the Aroon Indicator formed such a pattern. In 141 of the 166 cases the stock moved lower. This puts the odds of a downward move at 85%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NAMS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NAMS's RSI Indicator exited the oversold zone, 25 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 60 cases where NAMS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on NAMS as a result. In 67 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 71%.
The Moving Average Convergence Divergence (MACD) for NAMS just turned positive on October 20, 2026. Looking at past instances where NAMS's MACD turned positive, the stock continued to rise in 38 of 57 cases over the following month. The odds of a continued upward trend are 67%.
Following a +8.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where NAMS advanced for three days, in 199 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
NAMS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.085) is normal, around the industry mean (2.973). P/E Ratio (-9.991) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (357.143) is also within normal values, averaging (438.009).
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. NAMS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
IMVT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 54 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 26 Undervalued | |
PROFIT vs RISK RATING 1..100 | 60 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 63 | |
P/E GROWTH RATING 1..100 | 17 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| IMVT | NAMS | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 78% | 1 day ago 80% |
| Momentum ODDS (%) | N/A | 1 day ago 71% |
| MACD ODDS (%) | 1 day ago 89% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 66% |
| TrendMonth ODDS (%) | 1 day ago 80% | 1 day ago 71% |
| Advances ODDS (%) | 3 days ago 76% | 3 days ago 81% |
| Declines ODDS (%) | 7 days ago 81% | 9 days ago 78% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 88% | 1 day ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMVT’s FA Score shows that 1 FA rating(s) are green while NAMS’s FA Score has 2 green FA rating(s).
- IMVT’s FA Score: 1 green, 4 red.
- NAMS’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMVT’s TA Score shows that 4 TA indicator(s) are bullish while NAMS’s TA Score has 5 bullish TA indicator(s).
- IMVT’s TA Score: 4 bullish, 2 bearish.
- NAMS’s TA Score: 5 bullish, 3 bearish.
Price Growth
IMVT (@Biotechnology) experienced а +5.78% price change this week, while NAMS (@Biotechnology) price change was +7.40% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.17%. For the same industry, the average monthly price growth was -18.21%, and the average quarterly price growth was -15.24%.
Reported Earning Dates
IMVT is expected to report earnings on Nov 09, 2026.
NAMS is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Biotechnology (-1.17% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
IMVT and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +2.54% | ||
| ROIV - IMVT | 62% Loosely correlated | +1.77% | ||
| KURA - IMVT | 54% Loosely correlated | -0.20% | ||
| NAMS - IMVT | 45% Loosely correlated | +0.42% | ||
| DYN - IMVT | 45% Loosely correlated | -1.87% | ||
| SYRE - IMVT | 45% Loosely correlated | -0.67% | ||
More | ||||
NAMS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NAMS has been loosely correlated with VKTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NAMS jumps, then VKTX could also see price increases.
| Ticker / NAME | Correlation To NAMS | 1D Price Change % | ||
|---|---|---|---|---|
| NAMS | 100% | +0.42% | ||
| VKTX - NAMS | 45% Loosely correlated | -2.08% | ||
| IMVT - NAMS | 45% Loosely correlated | +2.54% | ||
| PTCT - NAMS | 43% Loosely correlated | +0.67% | ||
| KURA - NAMS | 42% Loosely correlated | -0.20% | ||
| RAPP - NAMS | 41% Loosely correlated | +5.87% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBIL | 24.28 | 0.22 | +0.93% |
| iShares iBonds Oct 2035 Term TIPS ETF (IBIL) | |||
| TALV | 28.96 | -0.04 | -0.13% |
| Transamerica Large Value Active ETF | |||
| TSLY | 21.70 | -0.65 | -2.91% |
| YieldMax TSLA Option Income Strategy ETF (TSLY) | |||
| ION | 38.94 | -1.30 | -3.23% |
| ProShares S&P Global Core Battery Metals ETF (ION) | |||
| SPXL | 280.41 | -10.46 | -3.60% |
| Direxion Daily S&P 500 Bull 3X ETF (SPXL) | |||